Biofidelity Raises $23M In Series A+ Financing Led By Octopus Ventures To Launch Aspyre Technology
02/01/22, 8:15 AM
Location
cambridgeMoney raised
$23 million
Round Type
series a
Biofidelity, a pioneer in precision cancer diagnostics, has successfully completed a heavily oversubscribed $23 million Series A+ investment round, led by Octopus Ventures and backed by SBI Investment Co. Ltd. and existing investors. The investment will fund the upcoming launch of ASPYRE-Lung, the company's first commercial diagnostic assay based on its breakthrough molecular technology.
Company Info
Location
cambridge, maryland, united states
Additional Info
Biofidelity is a pioneer in molecular diagnostics whose mission is to unlock the benefits of precision medicine for all patients by increasing access to early detection, precision diagnosis and routine monitoring with its revolutionary technologies.
Founded in 2019 in Cambridge, UK, Biofidelity is a rapidly growing private company that recently expanded to include both a U.S. headquarters and state-of-the-art clinical cancer diagnostic laboratory located in Research Triangle Park, North Carolina. For more information, visit biofidelity.com or connect on LinkedIn.